SEC Form 4 · accession 0001171843-17-007015
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brendan Delaney
Officer — Chief Commercial Officer
Period of report
Nov 10, 2017
Accepted (ET)
Nov 14, 2017 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1 | $12.40 | Nov 10, 2017 | A | 150,000 | A | — | Nov 10, 2024 | Common Stock, par value $0.01 per share | 150,000 | 150,000 | D |
Explanation of responses
- F1The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.